HC Wainwright Issues Optimistic Forecast for Myomo Earnings

Myomo, Inc. (NYSEAMERICAN:MYO) – Equities researchers at HC Wainwright boosted their Q1 2025 earnings per share estimates for shares of Myomo in a research note issued to investors on Wednesday, March 12th. HC Wainwright analyst S. Lee now expects that the company will post earnings of ($0.09) per share for the quarter, up from their previous estimate of ($0.11). HC Wainwright has a “Buy” rating and a $9.50 price objective on the stock. The consensus estimate for Myomo’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Myomo’s Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at ($0.13) EPS and FY2027 earnings at $0.20 EPS.

A number of other analysts have also recently commented on MYO. Craig Hallum boosted their price target on Myomo from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, March 11th. Alliance Global Partners reissued a “buy” rating on shares of Myomo in a research report on Tuesday, March 11th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $9.25.

Myomo Trading Up 2.4 %

Shares of MYO opened at $5.19 on Monday. Myomo has a 52 week low of $2.51 and a 52 week high of $7.17. The company has a market capitalization of $157.00 million, a PE ratio of -22.57 and a beta of 1.68.

Insider Buying and Selling

In related news, Director Thomas F. Kirk bought 7,400 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was acquired at an average cost of $5.00 per share, for a total transaction of $37,000.00. Following the purchase, the director now owns 255,933 shares in the company, valued at approximately $1,279,665. This represents a 2.98 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Micah Mitchell sold 48,000 shares of the business’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $5.16, for a total transaction of $247,680.00. Following the sale, the insider now owns 140,572 shares of the company’s stock, valued at approximately $725,351.52. This represents a 25.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.54% of the stock is owned by company insiders.

Institutional Investors Weigh In On Myomo

A number of hedge funds have recently added to or reduced their stakes in the stock. AIGH Capital Management LLC raised its stake in Myomo by 21.7% during the 4th quarter. AIGH Capital Management LLC now owns 3,381,567 shares of the company’s stock valued at $21,777,000 after buying an additional 602,719 shares during the last quarter. Soleus Capital Management L.P. purchased a new stake in Myomo during the 4th quarter valued at $5,796,000. Portolan Capital Management LLC purchased a new stake in Myomo during the 4th quarter valued at $2,446,000. Stonepine Capital Management LLC increased its stake in shares of Myomo by 174.4% in the 4th quarter. Stonepine Capital Management LLC now owns 274,426 shares of the company’s stock worth $1,767,000 after purchasing an additional 174,426 shares in the last quarter. Finally, Manatuck Hill Partners LLC purchased a new stake in shares of Myomo in the 4th quarter worth $1,582,000. 44.99% of the stock is currently owned by hedge funds and other institutional investors.

About Myomo

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.